EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects-Reference-Cited by-同舟云学术

EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects

Published:2022-02 Issue: Volume:146 Page:112532
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Paskeh Mahshid Deldar Abad,Mehrabi Atefeh,Gholami Mohammad Hossein,Zabolian Amirhossein,Ranjbar Ehsan,Saleki Hossein,Ranjbar Adnan,Hashemi Mehrdad,Ertas Yavuz Nuri,Hushmandi Kiavash,Mirzaei Sepideh,Ashrafizadeh Milad,Zarrabi Ali,Samarghandian Saeed

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference277 articles.

1. R. Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma 352(10) (2005) 987–996.

2. R. Stupp et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial 10(5) (2009) 459–466.

3. A.J. Grippin et al., Nanoparticles as immunomodulators and translational agents in brain tumors 151(1) (2021) 29–39.

4. M. Ashrafizadeh et al., C-Myc signaling pathway in treatment and prevention of brain tumors 21(1) (2021) 2–20.

5. Radioresistance in glioblastoma and the development of radiosensitizers;Ali;Cancers,2020

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PRMT6 facilitates EZH2 protein stability by inhibiting TRAF6-mediated ubiquitination degradation to promote glioblastoma cell invasion and migration;Cell Death & Disease;2024-07-23

2. Nanoliposomes as nonviral vectors in cancer gene therapy;MedComm;2024-06-25

3. EZH2‐associated tumor malignancy: A prominent target for cancer treatment;Clinical Genetics;2024-06-17

4. Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis;Molecular Medicine;2024-06-17

5. Autophagy flux in bladder cancer: Cell death crosstalk, drug and nanotherapeutics;Cancer Letters;2024-06